Navigation Links
Better vision ahead for many diabetic retinopathy patients
Date:4/27/2010

SAN FRANCISCO, CAA nationwide, government-sponsored study finds that people with a common form of diabetic retinopathy can benefit from a medication first developed to combat another potentially blinding disease, age-related macular degeneration (AMD). Treating diabetic macular edema (DME) with ranibizumab (Lucentis) eye injections, plus laser treatment if needed, appears to result in better vision than laser treatment alone, according to the Diabetic Retinopathy Clinical Research (DRCR) Network study published today in Ophthalmology online, the journal of the American Academy of Ophthalmology (Academy). DME is the main cause of vision loss in people with diabetes mellitus.

At the one year follow-up, nearly 50% of study patients who received the new combined treatment had substantial improvement in vision, compared with 28% who received laser treatment alone. Laser treatment has been the standard of care for DME for 25 years.

"The results appear to be applicable to most people who have DME in the center of the macula with some vision loss, whether the person has Type 1 or Type 2 diabetes, is old or young, or is a woman or a man," said Neil M. Bressler, MD, the Chair of the nationwide DRCR Network, and Chief of the Retina Division, Wilmer Eye Institute, Johns Hopkins University School of Medicine.

"This is a seminal study of which ophthalmology should be very proud," said George A. Williams, MD, an Academy board member and Ophthalmology Department Chair, Oakland University William Beaumont School of Medicine. "First and most importantly, it provides patients an improved therapy for diabetic macular edema. Second, the DRCR Network study is the first multi-center, randomized clinical trial to show how ranibizumab and the laser work together to improve treatment."

The DRCR Network investigators studied 854 eyes (691 participants) at 52 clinical centers across the United States, and compared four treatment modalities: ranibizumab plus prompt laser treatment, ranibizumab plus deferred laser treatment (provided at 24 weeks or later, if indicated), a coritcosteroid (triamcinolone) eye injection plus prompt laser treatment, or prompt laser treatment alone.

At the one year follow up patients who had received ranibizumab with prompt or deferred laser treatment had, on average, significantly better visual acuity than the group treated with laser alone. Also, significantly more patients in the ranibizumab-treated groups gained vision, and fewer suffered vision loss. In patients who entered the study after having cataract surgery and lens implants, results for corticosteroids plus laser treatment appeared comparable to the ranibizumab results, but intraocular pressure (IOP) increased in some corticosteroid-treated patients. Elevated IOP is undesirable because it can increase the risk of glaucoma. Negative outcomes were minimal in patients treated with ranibizumab. Results at two years were comparable to year one, but the researchers urge further study to confirm the longer-term safety and effects of ranibizumab for diabetic macular edema patients.

"In the brave new world of health care reform, the DRCR Network will serve as a model for future comparative effectiveness studies," Dr. Williams said.

The Academy will review the DRCR Network results and recommendations to determine whether, going forward, ranibizumab plus laser treatment should be a preferred treatment for most patients with diabetic macular edema with characteristics similar to those enrolled in this DRCR Network study.

Drs. Bressler and Williams emphasize that people with diabetes should ask their ophthalmologists (Eye M.D.s) if the new treatment approach might be appropriate for them. Although ranibizumab is an FDA-approved drug for AMD, it is not yet specifically approved for use with DME. Not every insurance company covers its use for DME at this time, since the definitive DRCR Network study results have just been published, although some insurance companies currently do cover this use based on previous smaller studies with briefer follow-up. Also, the DRCR Network study did not evaluate a very similar drug, bevacizumab (Avastin), so definitive confirmation of its potential effectiveness in DME is not yet available.


'/>"/>

Contact: Mary Wade
mwade@aao.org
415-447-0221
American Academy of Ophthalmology
Source:Eurekalert

Related medicine news :

1. Brown Rice Tied to Better Heart Health in Study
2. Life Coach and Author Thomas Finn's Highly Anticipated Book, 'A Better Tomorrow- Affirmations and Visualizations the Keys to Success,' Debuts June 15
3. Is patient coding making hospitals appear better than they are?
4. Better vitamin D status could mean better quality of life for seniors
5. Get a Better Shave in Less Time With New Waterless Shave Product
6. Glued graft for Pterygium Yield Better Cosmetic Results
7. Better Teachers Make for Stronger Young Readers
8. Better patient safety linked to fewer medical malpractice claims in California
9. Better Treatment Found for Crohns Disease
10. Flu Vaccine With Both B Strains May Offer Better Protection
11. M. D. Anderson zeroes in on better way to predict prognosis in pediatric leukemia patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... ... , ... TransWipe Volume 3 is a set of 30 professional transition animations ... between two video clips to instantly add a unique transition to any Final Cut ... and orientation options. TransWipe Volume 3 is a Final Cut Pro X exclusive plugin. ...
(Date:5/5/2016)... (PRWEB) , ... May 05, 2016 , ... While the ... being paid to the impact our aging population has on communities and resources. Aging ... adults plan for and face age-related challenges. , Aging Life Care is a ...
(Date:5/5/2016)... , ... May 05, 2016 , ... ... overall select performance in the industry’s gold standard KLAS Performance Report, ... Epic Consulting report assessed organizations that specialize in consulting services for electronic health ...
(Date:5/5/2016)... , ... May 05, 2016 , ... ... long-acting injectables (LAIs), today announced a development collaboration with the Australian critical ... serious mental disorders such as schizophrenia. , LAI medicines can offer improved therapeutic ...
(Date:5/5/2016)... ... 05, 2016 , ... Textile Exchange is excited to announce the ... review. The stakeholder review is an important opportunity for interested parties to give input ... to the wool industry., The RWS is intended to be a global benchmark for ...
Breaking Medicine News(10 mins):
(Date:5/5/2016)... , May 6, 2016 ... of liver disorders along with rise in obesity ... drugs in the coming few years. The NASH ... last five years on account of rising number ... is a large, un-tapped market with no FDA ...
(Date:5/5/2016)... reported initial promising results in animal trials of its Zika vaccine candidates. ... ... ... ... analysis identified the highest gene Replikin Counts in Zika history back to 1946 (1). ...
(Date:5/5/2016)... May 5, 2016  Endo International plc (NASDAQ: ... that Brian Lortie , President, U.S. Branded ... position upon the appointment of a successor. Mr. ... U.S. Pharmaceuticals business with responsibility for all strategic, ... strategy and portfolio development, commercial operations, managed markets, ...
Breaking Medicine Technology: